Clinical Trials Watch — 2026-04-19

TITLE: Clinical Trials Watch — Week of Apr 19, 2026: Phase III miniscrew readout, ARFI prostate biopsy terminated

---

This Week's Signal

A light but varied slate this week across ClinicalTrials.gov activity updates. One Phase III readout (dental devices), one terminated imaging study in prostate cancer, and one withdrawn ICU sedation protocol. Oncology, metabolic, and nephrology supportive-care studies round out the list. Grouping below by phase.

---

Phase III — Readouts

Coated Orthodontic Miniscrews (Completed)

• Trial: NCT06124235 — Assessment of Coated Orthodontic Miniscrews With Chlorhexidine Hexametaphosphate Antimicrobial Nanoparticles
• Condition: Orthodontic appliance complications
• Intervention: Chlorhexidine hexametaphosphate-coated vs. uncoated miniscrews (combination product)
• Status: COMPLETED (Feb 2023 – Dec 2023)
• Flag: 🟢 Phase III readout. Device/combination-product study; narrow indication but relevant for antimicrobial coating platforms. Sponsor disclosure and primary endpoint (peri-implant infection rates / miniscrew stability) not specified in the feed — watch for publication.

---

Phase IV

Lactoferrin Add-On for CKD Anemia

• Trial: NCT05900635 — Effect of Adding Lactoferrin on Oral Iron on Anemia in CKD
• Condition: Anemia of chronic kidney disease
• Interventions: Lactoferrin + ferrous glycine sulfate vs. oral iron alone
• Status: UNKNOWN (listed completion Sep 2023; record stale)
• Note: Supportive-care augmentation study. Primary endpoint not disclosed in feed; likely Hb response. Record status suggests no recent sponsor update.

---

Phase II (incl. Phase I/II)

Doxorubicin + Paclitaxel in Locally Advanced Breast Cancer

• Trial: NCT00003035
• Condition: Breast cancer (locally advanced)
• Regimen: Doxorubicin, paclitaxel, tamoxifen, filgrastim support, ± surgery/RT
• Status: COMPLETED (legacy 1997–2001 record; activity update only)

EndoSaver Corneal Endothelium Delivery Device

• Trial: NCT00874835
• Condition: Corneal transplantation
• Intervention: EndoSaver™ delivery instrument
• Status: UNKNOWN (legacy record, completion Oct 2010)

Doxorubicin Drug-Eluting Microspheres TACE in HCC (Phase I/II)

• Trial: NCT01116635
• Condition: Hepatocellular carcinoma
• Intervention: Doxorubicin-loaded superabsorbent polymer microspheres, transarterial embolization
• Status: COMPLETED (2010–2012 record)

---

Phase I

*No new Phase I activity in this week's feed.*

---

Non-Phased / Observational / Device

NAFLD Prevalence in T2DM

• Trial: NCT06445335
• Conditions: NAFLD, Type 2 diabetes
• Intervention: FibroScan (diagnostic)
• Status: ACTIVE_NOT_RECRUITING; completion Nov 2026
• Note: Prevalence/epidemiology study; FibroScan-based screening in a T2D cohort. Useful real-world denominator data for resmetirom-era MASH commercial modeling.

Flaxseed + Hesperidin in Metabolic Syndrome

• Trial: NCT03734835
• Condition: Metabolic syndrome
• Status: UNKNOWN (stale record)

Airway Hyperresponsiveness in Elite Swimmers

• Trial: NCT00876135
• Condition: Asthma; intervention: albuterol (Ventolin)
• Status: COMPLETED (legacy)

---

🔴 Terminations & Withdrawals

ARFI Imaging for Targeted Prostate Biopsy — TERMINATED

• Trial: NCT04607135
• Condition: Prostate cancer
• Intervention: Acoustic radiation force impulse (ARFI) + ultrasound
• Status: TERMINATED (Oct 2021 – Mar 2023)
• Read-through: Another setback for non-MRI targeted biopsy imaging modalities. Reason for termination not disclosed in the record — monitor for sponsor update. MRI-fusion biopsy remains standard.

Analgosedation Protocol in Mechanically Ventilated Patients — WITHDRAWN

• Trial: NCT02100735
• Condition: ICU mechanical ventilation duration
• Status: WITHDRAWN (no enrollment; 2019 start, 2021 closeout)
• Note: Protocolized sedation study never launched patient accrual.

---

Editor's Take

• Phase III highlight of the week is narrow: a dental antimicrobial-coating readout (NCT06124235). No large-cap oncology or cardiometabolic Phase III crossed the wire in this batch.
• ARFI termination (NCT04607135) is the most commercially relevant negative signal — reinforces the MRI-fusion moat in prostate biopsy workflow.
• Data hygiene flag: multiple UNKNOWN-status records surfaced in this week's activity feed (NCT03734835, NCT05900635, NCT00874835). These are likely auto-flagged stale records rather than genuine new activity — interpret accordingly.
• To watch next week: MASH/NAFLD prevalence readout from NCT06445335 as it nears its Nov 2026 primary completion.

Sponsor identities and primary endpoints were not provided in the upstream feed for most records; we've flagged where disclosure is incomplete rather than inferring.